Sign in23 stories
A phase II study combining DA-EPOCH chemotherapy with Jazz Pharmaceuticals' recombinant Erwinia asparaginase in newly diagnosed adult leukemia patients was halted, per its ClinicalTrials.gov record last updated.
ClinicalTrials.gov
The genetic medicines company named Sebulsky a Class I director effective September 23, 2026, with a term running until the 2028 annual meeting.
SEC filing
Jazz Lux amended its credit agreement on September 23, 2026, cutting the interest margin by 50 basis points and pushing the maturity date out five years to 2033.
SEC filing
The former FDA official and regulatory consultant joins as a Class II director effective September 15, 2026.
SEC filing
The $820 million deal brings Jazz an oral KCNT1 inhibitor for KCNT1-related epilepsy that has shown seizure reductions in an early pediatric trial.
SEC filing
The notes carry a 1.875% coupon and mature in 2032, with proceeds slated for general corporate purposes and a $225 million share buyback.
SEC filing
The approval triggers a $250 million milestone payment to Zymeworks from partner Jazz Pharmaceuticals, with more payments and royalties possible.
SEC filing
Jazz Pharmaceuticals said the agency cleared zanidatamab-hrii with and without tislelizumab plus chemotherapy for all HER2+ patients regardless of PD-L1 status.
SEC filing
The company keeps its WTX-124 and WTX-330 clinical programs through a new license from EMD while non-clinical assets change hands.
SEC filing
PLN-101095 trial enrollment is running ahead of schedule ahead of 2027 interim data, while the company outlines new board additions and cash into second half of 2028.
SEC filing
The deal adds ABS-1230, a precision therapy for KCNT1+ epilepsy, plus up to $500 million in contingent milestones.
SEC filing
The deal, signed August 10, 2026, centers on epilepsy drug candidate ABS-1230 and includes milestone payments tied to regulatory approval and sales targets.
SEC filing
Zymeworks said the FDA's target action date on zanidatamab in gastric cancer falls on August 25, 2026, while the Theravance Biopharma acquisition is still expected to close in the second half of the year.
SEC filing
The company also detailed new HER2-positive breast cancer data, an on-track ALX2004 safety readout, and $153.4 million in cash.
SEC filing
The company cited new drug approvals and an expanded pipeline as it lifted its full-year Portfolio Receipts outlook to $3,400 million to $3,500 million.
SEC filing
Jazz reported record quarterly revenue of $1.2 billion and set up a possible near-term launch of Ziihera in a new gastric cancer indication.
SEC filing
Werewolf said it expects to report strategic-review and clinical trial updates in the second half of 2026 after closing its JZP898 sale to Jazz and repaying its K2 loan.
SEC filing